Aspire Biopharma Holdings (ASBP) Invested Capital (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Invested Capital for 5 consecutive years, with $11.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital rose 351.89% year-over-year to $11.8 million in Q2 2026; TTM through Jun 2026 was $11.8 million, a 351.89% increase from a year earlier, with the FY2025 full-year figure at -$3.3 million, down 123.85% from the prior year.
• Invested Capital was $11.8 million for Q2 2026 at Aspire Biopharma Holdings, up from $4.4 million in the prior quarter.
• Over five years, Invested Capital peaked at $14.0 million in Q4 2024 and troughed at -$4.7 million in Q2 2025.
• A 4-year average of $2.3 million and a median of -$55283.0 in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital surged 13752.08% in 2024 and slumped 6350.52% in 2025, its largest moves.
• Over 4 years, Invested Capital stood at -$102457.0 in 2023, then surged by 13752.08% to $14.0 million in 2024, then slumped by 123.85% to -$3.3 million in 2025, then surged by 452.52% to $11.8 million in 2026.
• The last three Invested Capital figures came in at $11.8 million (Q2 2026), $4.4 million (Q1 2026), and -$3.3 million (Q4 2025), per Business Quant data.